Cannabis Act

Christina Lake Cannabis Further Strengthens Board of Directors and Management Team

Retrieved on:

Monday, December 12, 2022

“As Christina Lake continues to strengthen its position in the market, we are looking forward to the expertise and deep industry knowledge that Jay will bring to the role of Chairman,” said Mark Aiken, CEO of Christina Lake.

Key Points:

“As Christina Lake continues to strengthen its position in the market, we are looking forward to the expertise and deep industry knowledge that Jay will bring to the role of Chairman,” said Mark Aiken, CEO of Christina Lake.
Prior to his role at Christina Lake, he held the position of Director of Key Accounts at Aurora Cannabis.
About Christina Lake Cannabis Corp.
Christina Lake Cannabis is a licensed producer of cannabis under the Cannabis Act.
Christina Lake Cannabis also owns a 99-acre plot of land adjoining its principal site.

Health Canada releases new data on cannabis use in Canada

Retrieved on:

Friday, December 16, 2022

PETS, Health Canada, Ageing, Alcohol, Cannabis Act, Sale, Eating, Government of Canada, Policy, COVID-19, Smoking, Government, Cannabis, Drug, Medicinal plants

The 2022 Canadian Cannabis Survey provides important insights into Canadians' knowledge, attitudes and behaviours on cannabis use

Key Points:

The 2022 Canadian Cannabis Survey provides important insights into Canadians' knowledge, attitudes and behaviours on cannabis use
OTTAWA, ON, Dec. 16, 2022 /CNW/ - The Government of Canada collects data to better understand how Canadians view and use cannabis.
Through this data, we can bettermonitor Canada's national framework for controlling the production, distribution, sale and possession of cannabis under the Cannabis Act.
Today, Health Canada published the results of the 2022 Canadian Cannabis Survey .
Health Canada has conducted the Canadian Cannabis Survey every year since 2017.

Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada

Retrieved on:

Thursday, December 8, 2022

Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (KGK), has been awarded an institution wide cannabis research license (the Research License) for their new state-of-the-art facility by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development (R&D).

Key Points:

Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (KGK), has been awarded an institution wide cannabis research license (the Research License) for their new state-of-the-art facility by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development (R&D).
The Research License greatly reduces the timelines required for conducting cannabis research and facilitates the ability for KGK to apply for cannabis import permits without first having to obtain project-specific research licenses.
The Research License allows KGK to conduct clinical trials investigating cannabis for both non-therapeutic and therapeutic purposes, as well as on-site sensory assessments of cannabis products, without having to obtain project specific cannabis research licenses, ultimately accelerating our research programs and reducing the time to market, added Najla Guthrie, CEO of Wellbeing Digital and KGK Science.
Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

Organigram Wins KIND Magazine’s Cannabis Company of the Year Award and Most Innovative Product of the Year for Edison JOLTS

Retrieved on:

Thursday, December 8, 2022

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of a leading licensed producer of cannabis (the Company or Organigram), is pleased to announce it has won KIND Magazines (KIND) Cannabis Company of the Year award.

Key Points:

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of a leading licensed producer of cannabis (the Company or Organigram), is pleased to announce it has won KIND Magazines (KIND) Cannabis Company of the Year award.
The Cannabis Company of the Year award is particularly special because it not only acknowledges Organigram as a top performing licensed producer, but also celebrates the high-quality of our talented employees from coast-to-coast.
Likewise, the award is unique as it considers purpose, recognizing Organigrams commitment to doing good in the communities we serve.
In addition to the Cannabis Company of the Year award, the Companys Edison Cannabis Co. brands Edison JOLTS, Canadas first high-potency lozenge, received the Most Innovative Product of the Year.

Health Canada finalizes amendments on cannabis research and testing, and cannabis beverages

Retrieved on:

Friday, December 9, 2022

Health Canada, THC, Cannabis Act, Dutch Association of Mental Health and Addiction Care, Public health, Act, Sale, Part Two, Research, Regulatory impact analysis, Canada Gazette, Government, Cannabis, Mental health, University, Chocolate, Medical device, Drug, Health

OTTAWA, ON, Dec. 9, 2022 /CNW/ - Today, Health Canada announced that amendments to the Cannabis Act and its regulations concerning cannabis research and testing, and cannabis beverages have been approved and are now in force as of December 2, 2022.

Key Points:

OTTAWA, ON, Dec. 9, 2022 /CNW/ - Today, Health Canada announced that amendments to the Cannabis Act and its regulations concerning cannabis research and testing, and cannabis beverages have been approved and are now in force as of December 2, 2022.
These amendments follow extensive engagement with stakeholders, universities, researchers, health authorities, cannabis industry associations, cannabis licence holders, provinces, territories and the public.
They aim to facilitate research and testing, and also amend the public possession limit for cannabis beverages to bring them in line with other cannabis products.
Increase the public possession limit for cannabis beverages to a level that is similar to other forms of cannabis, such as solid edible cannabis products (i.e.

Agra Ventures’ Boundary Bay Cannabis JV Receives Over $910,000 in Purchase Orders in Last 3 Months

Retrieved on:

Tuesday, November 29, 2022

Bay, THC, OTC, Cannabis Act, United Kingdom, Joint venture, International joint venture, Cannabis, Joint, Interim, BBC, SEDAR, News, CBD, Sale, Boundary Bay, CSE, Information services, Drug

The purchase orders were received from multiple parties and represent a total of over 725,000 grams of processed product.

Key Points:

The purchase orders were received from multiple parties and represent a total of over 725,000 grams of processed product.
Id like to thank the staff and BBCs sales agent for doing their part to grow great cannabis and secure these purchase orders.
Agra Ventures primary asset in Canada is its 70% ownership of Boundary Bay Cannabis located in Delta, BC.
Boundary Bay Cannabis utilizes part of a large greenhouse complex in order to focus on the cost-optimized cultivation of high-potency cannabis.

High Tide Launches Exclusive Paid Membership Program: "Cabana Elite"

Retrieved on:

Tuesday, November 29, 2022

We are confident ELITE will generate excellent returns for our shareholders, who can rely on High Tide for continued innovation and execution," added Mr. Grover.

Key Points:

We are confident ELITE will generate excellent returns for our shareholders, who can rely on High Tide for continued innovation and execution," added Mr. Grover.
In addition, High Tide announces the grant of an aggregate of 25,000 incentive stock options (the "Options") to certain employees of the Company.
High Tide is a leading retail-focused cannabis company with bricks-and-mortar as well as global e-commerce assets.
For more information about High Tide, please visit www.hightideinc.com and its profile pages on SEDAR at www.sedar.com and EDGAR at www.sec.gov .

High Tide Launches Exclusive Paid Membership Program: “Cabana Elite”

Retrieved on:

Tuesday, November 29, 2022

Once our customers see what ELITE has to offer, we anticipate they will look to maintain their status in subsequent years.

Key Points:

Once our customers see what ELITE has to offer, we anticipate they will look to maintain their status in subsequent years.
Launching ELITE was not an easy task, given the varied regulatory landscape in the Canadian provinces where we operate.
We are confident ELITE will generate excellent returns for our shareholders, who can rely on High Tide for continued innovation and execution, added Mr. Grover.
In addition, High Tide announces the grant of an aggregate of 25,000 incentive stock options (the Options) to certain employees of the Company.

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Retrieved on:

Thursday, November 17, 2022

Organigram and InterCure entered into a previous strategic supply agreement in June 2020, (the First Strategic Agreement) that contemplated a minimum supply of 3,000 kg all of which has been fulfilled.

Key Points:

Organigram and InterCure entered into a previous strategic supply agreement in June 2020, (the First Strategic Agreement) that contemplated a minimum supply of 3,000 kg all of which has been fulfilled.
The New Strategic Agreement contemplates up to 20,000 kg to be supplied to InterCure's international supply chain.
Approximately 2,800 kg has already been delivered to Canndoc from Organigram since July 2022 and credited against the total volume commitment under the New Strategic Agreement.
Subject to the terms and conditions of the New Strategic Agreement, Organigram has agreed to exclusively supply InterCure in Israel for the Term.

Organigram Launches HOLY MOUNTAIN to Further Support Its Strong Position in the Dried Flower and Hash Categories

Retrieved on:

Wednesday, November 23, 2022

With the introduction of HOLY MOUNTAIN, Organigram will now offer value-priced flower in an expanded range of sizes, starting with 3.5g offerings at launch and additional sized formats expected soon after.

Key Points:

With the introduction of HOLY MOUNTAIN, Organigram will now offer value-priced flower in an expanded range of sizes, starting with 3.5g offerings at launch and additional sized formats expected soon after.
View the full release here: https://www.businesswire.com/news/home/20221123005144/en/
The HOLY MOUNTAIN brand will feature iconic flower cultivars including MAC-1 and R*NTZ.
Additionally, the 2g Pressed Hash Cube represents the newest hash product being produced at our Quebec-based hash facility located in the foothills of the Tremblant Mountain, says Eric Williams Senior Director of Marketing at Organigram.
Finally, Organigram has launched new value brand W L, which has the same value flower focus as HOLY MOUNTAIN but created specifically for the Quebec market.